Syndax Pharmaceuticals Inc

SNDX

Syndax Pharmaceuticals Inc

SNDX

Insider Sentiment (TTM):

Last Purchase:2025-05-19Last Sale:2026-06-12Shares Purchased (TTM):0Shares Sold (TTM):226,629

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:97,794,497Shares Outstanding:88,255,636Institutional Ownership Pct.:110.81%

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	336	131	135	117	109	154	154	133	105	115	295	95
Short Term Investments	211	221	259	319	347	358	419	257	320	320	275	269
Accounts Receivable Net Current	-	-	38	-	-	-	8	-	-	-	0	-
Inventory Gross	-	-	33	-	-	-	0	-	-	-	0	-
Accounts And Other Receivables Net Current	45	38	-	25	19	16	-	-	-	-	-	-
Inventory Net	33	35	-	25	18	5	-	-	-	-	-	-
Deposits Assets Current	6	9	20	18	13	4	10	17	7	9	7	10
Other Assets Current	-	-	-	-	-	-	-	4	10	6	-	-
Other Receivables	3	0	6	0	4	4	4	-	-	-	0	-
Prepaid Expense And Other Assets Current	17	16	13	10	10	8	9	5	4	5	3	4
Assets Current	675	471	528	530	532	549	603	415	446	454	581	381
Long Term Investments	-	-	0	20	63	90	120	10	30	87	30	16
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	1	1	1	1	2	2	2	1	1	1	1	2
Other Assets Noncurrent	-	-	-	-	-	-	0	0	0	0	0	1
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	704	473	530	552	596	641	725	426	477	543	613	399
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	11	17	14	17	10	12	5	12	9	10	6
Accrued Liabilities And Other Liabilities	94	75	103	77	71	56	60	48	27	33	40	32
Loans Payable To Bank Current	-	-	0	-	-	-	12	-	-	-	0	-
Operating Lease Liability Current	1	0	0	0	0	0	0	1	1	1	1	1
Liabilities Current	100	86	120	114	113	95	104	59	42	51	58	39
Liabilities Noncurrent
Long Term Notes Payable	-	-	-	-	-	-	332	-	-	-	0	-
Liabilities Noncurrent	589	345	345	322	326	331	333	0	0	0	1	1
Operating Lease Liability Noncurrent	-	-	-	-	-	-	2	0	0	0	1	1
Liabilities	689	431	465	436	439	426	437	59	43	51	59	40
Stockholders Equity
Preferred Stock Value	-	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,614	1,591	1,571	1,553	1,535	1,521	1,509	1,493	1,478	1,467	1,456	1,190
Accumulated Other Comprehensive Income Loss Availa…	-0	0	0	1	0	1	0	0	-1	-1	0	-0
Retained Earnings Accumulated Deficit	-1,599	-1,549	-1,507	-1,439	-1,378	-1,306	-1,221	-1,127	-1,043	-975	-902	-830
Stockholders Equity	15	42	65	115	157	215	288	366	434	492	554	359
Liabilities And Stockholders Equity	704	473	530	552	596	641	725	426	477	543	613	399
Preferred Stock Par Or Stated Value Per Share	-	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	-	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Outstanding	-	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	100
Common Stock Shares Issued	89	89	-	87	86	86	-	86	85	85	-	70
Shares Outstanding	89	89	87	87	86	86	86	86	85	85	85	70

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.95%	-11.34%	6.39%	-	-	-	-	-	-	-	-	-
2025	-22.33%	-33.38%	-29.03%	57.32%	51.06%	30.35%	44.04%	54.80%	47.17%	17.22%	17.22%	-2.13%
2024	-13.90%	-8.27%	9.43%	-6.45%	-16.95%	-10.41%	-15.08%	-35.14%	-27.63%	-14.86%	-13.89%	-36.37%
2023	-	-	-	-	-	-	4.87%	41.68%	39.92%	-7.50%	-14.79%	-16.88%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.77	5.47	4.40	4.64	4.71	5.80	5.82	6.99	10.50	8.93	10.00	9.73
Quick Ratio	6.26	4.88	4.01	4.34	4.46	5.66	5.74	6.90	10.40	8.84	9.94	9.63
Working Capital	575.36M	385.00M	407.97M	415.64M	418.69M	454.20M	499.51M	355.43M	403.58M	403.09M	522.78M	341.80M
Leverage & Debt
Debt to Equity	45.60	10.36	7.20	3.78	2.79	1.98	1.52	0.16	0.10	0.10	0.11	0.11
Interest Coverage TTM	-97,085.50	-55,882.25	-45,514.00	-2,360.78	-2,216.03	-1,772.76	-1,375.19	-1,726.95	-1,236.01	-1,181.40	-1,105.55	-1,032.35
Debt Ratio	0.98	0.91	0.88	0.79	0.74	0.66	0.60	0.14	0.09	0.09	0.10	0.10
Efficiency & Turnover
Asset Turnover TTM	0.39	0.39	0.27	0.23	0.15	0.07	0.04	0.04	0.01	0.00	0.00	0.00
Days Sales Outstanding TTM	-	-	48.28	-	-	-	117.18	-	-	-	-	-
Receivables Turnover TTM	-	-	7.56	-	-	-	3.11	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.48	-2.76	-3.29	-3.60	-3.88	-3.84	-3.72	-3.48	-3.10	-2.82	-2.98	-2.52
Free Cash Flow Per Share TTM	-2.48	-3.15	-3.73	-3.59	-3.51	-3.32	-3.21	-3.03	-2.83	-2.40	-2.28	-2.03
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-77.05%	-102.93%	-158.45%	-275.12%	-433.68%	-786.59%	-1,434.43%	-2,007.58%	-8,228.31%	-	-	-
Net Profit Margin TTM	-87.60%	-112.01%	-165.60%	-279.31%	-428.48%	-757.52%	-1,346.11%	-1,856.64%	-7,545.20%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	222.34%	396.72%	627.84%	597.19%	2,133.71%	-	-	-	-	-	-	-100.00%
Net Income Growth (1Y)	-34.10%	-26.56%	-10.46%	4.89%	26.85%	37.64%	52.25%	68.71%	64.70%	56.97%	40.19%	1,162.59%
EPS Growth (1Y)	-36.06%	-28.29%	-11.50%	3.45%	25.29%	36.11%	25.13%	37.95%	34.50%	27.92%	21.05%	996.57%
Valuation Metrics
P/E TTM	-8.81	-8.48	-6.38	-4.28	-2.41	-3.20	-3.55	-5.54	-6.63	-8.43	-7.26	-5.76
P/B TTM	128.84	49.53	28.16	11.55	5.14	4.92	3.93	4.49	4.03	4.12	2.74	2.82
P/S TTM	7.72	9.49	10.56	11.95	10.34	24.21	47.80	102.79	500.20	-	-	-
Market Cap	1.95B	2.06B	1.82B	1.33B	808.55M	1.06B	1.13B	1.64B	1.75B	2.03B	1.52B	1.01B
Enterprise Value	1.61B	1.93B	1.69B	1.22B	699.91M	904.63M	1.31B	1.51B	1.65B	1.91B	1.23B	919.76M
Calculated Values
Free Cash Flow TTM	-220.64M	-278.16M	-322.98M	-310.88M	-302.67M	-286.52M	-274.90M	-258.86M	-241.20M	-204.92M	-160.60M	-142.15M
Net Debt	-336.48M	-130.89M	-134.93M	-116.81M	-108.64M	-153.99M	177.48M	-133.02M	-105.40M	-114.62M	-295.39M	-94.55M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-12Sale

Owner: Botwood, Nicholas A.J.

Title: Head of R&D, CMO

Shares: 31,235

Price/Share: $18.14

Value: $566,602.90

Shares Owned: 60,885

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Metzger, Michael A

Title: Chief Executive Officer

Shares: 6,847

Price/Share: $18.99

Value: $130,024.53

Shares Owned: 484,843

Relationship: Director,Officer

Ownership: Direct

2026-06-01Sale

Owner: Goldan, Keith A.

Title: Chief Financial Officer

Shares: 1,177

Price/Share: $18.99

Value: $22,351.23

Shares Owned: 139,252

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Goldan, Keith A.

Title: Chief Financial Officer

Shares: 3,410

Price/Share: $21.03

Value: $71,712.30

Shares Owned: 140,429

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Metzger, Michael A

Title: Chief Executive Officer

Shares: 17,159

Price/Share: $21.03

Value: $360,853.77

Shares Owned: 491,690

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-12	Botwood, Nicholas A.J.	Officer	Head of R&D, CMO	Direct	Sale	31,235	18.14	$566,602.90	60,885	4
2026-06-01	Metzger, Michael A	Director,Officer	Chief Executive Officer	Direct	Sale	6,847	18.99	$130,024.53	484,843	4
2026-06-01	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Sale	1,177	18.99	$22,351.23	139,252	4
2026-02-09	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Sale	3,410	21.03	$71,712.30	140,429	4
2026-02-09	Metzger, Michael A	Director,Officer	Chief Executive Officer	Direct	Sale	17,159	21.03	$360,853.77	491,690	4
2026-02-06	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Sale	2,082	20.62	$42,930.84	143,839	4
2026-02-06	Metzger, Michael A	Director,Officer	Chief Executive Officer	Direct	Sale	7,412	20.62	$152,835.44	508,849	4
2025-09-08	Metzger, Michael A	Director,Officer	Chief Executive Officer	Direct	Sale	157,307	16.41	$2,581,407.87	298,661	4
2025-08-18	Podlesak, Dennis	Director	-	Direct	Sale	19,200	15.84	$304,128.00	191,763	4
2025-07-16	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Sale	1,296	9.29	$12,039.84	92,450	4
2025-07-16	Metzger, Michael A	Director,Officer	Chief Executive Officer	Direct	Sale	7,534	9.29	$69,990.86	298,661	4
2025-05-19	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Purchase	3,000	-	-	93,746	4
2025-05-19	Katkin, Keith	Director	-	Direct	Purchase	10,000	9.11	$91,100.00	100,000	4
2025-05-19	Huber, Martin H. Jr.	Director	-	Direct	Purchase	5,000	8.99	$44,950.00	79,000	4
2025-05-16	Botwood, Nicholas A.J.	Officer	Head of R&D, CMO	Direct	Purchase	11,765	9.00	$105,885.00	35,165	4
2025-03-04	Metzger, Michael A	Director,Officer	Chief Executive Officer	Direct	Sale	7,814	15.05	$117,600.70	300,121	4
2025-02-10	Metzger, Michael A	Director,Officer	Chief Executive Officer	Direct	Sale	13,288	15.50	$205,964.00	300,121	4
2025-02-10	Gallagher, Neil	Officer	President, Head of R&D	Direct	Sale	4,618	15.50	$71,579.00	85,095	4
2025-02-10	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Sale	3,777	15.50	$58,543.50	90,746	4
2024-06-14	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Purchase	1,250	20.03	$25,037.50	52,623	4
2023-08-09	Morrison, Briggs	Director	-	Direct	Sale	52,855	18.27	$965,660.85	17,836	4
2023-08-02	Meury, William	Director	-	Direct	Sale	83,000	20.46	$1,698,180.00	48,000	4
2023-07-10	Morrison, Briggs	Director	-	Direct	Sale	52,855	20.40	$1,078,242.00	17,836	4
2023-06-13	Goldan, Keith A.	Officer	Chief Financial Officer	Direct	Sale	577	22.31	$12,872.87	2,628	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

110.81%

Inst. Shares: 97,794,497

Shares Outstanding: 88,255,636

2025-12-31

112.18%

Inst. Shares: 97,178,784

Shares Outstanding: 86,625,610

2025-09-30

113.92%

Inst. Shares: 98,677,476

Shares Outstanding: 86,620,992

2025-06-30

114.11%

Inst. Shares: 98,515,427

Shares Outstanding: 86,337,237

2025-03-31

112.47%

Inst. Shares: 96,918,463

Shares Outstanding: 86,171,889

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	97,794,497	88,255,636	110.81%
2025-12-31	97,178,784	86,625,610	112.18%
2025-09-30	98,677,476	86,620,992	113.92%
2025-06-30	98,515,427	86,337,237	114.11%
2025-03-31	96,918,463	86,171,889	112.47%
2024-12-31	95,541,369	85,622,065	111.58%
2024-09-30	86,616,495	85,433,569	101.38%
2024-06-30	85,500,512	85,274,829	100.26%
2024-03-31	86,591,778	85,213,200	101.62%
2023-12-31	84,427,929	70,370,519	119.98%
2023-09-30	68,141,265	69,855,766	97.55%
2023-06-30	68,280,125	69,638,427	98.05%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Syndax Pharmaceuticals Inc (SNDX) — SEC Financial Statements & Analysis

Syndax Pharmaceuticals Inc (SNDX) is a pharmaceutical preparations company, incorporated in DE. Syndax Pharmaceuticals Inc trades on Nasdaq as: SNDX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Syndax Pharmaceuticals Inc reported a 222.34% year-over-year revenue growth, a Debt-to-Equity ratio of 45.60x, a Price-to-Sales (P/S) ratio of 7.72x (TTM), a Price-to-Book (P/B) ratio of 128.84x (TTM), at a market cap of $1.95B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 222.34%
Debt To Equity: 45.60x
P/S TTM: 7.72x
P/B TTM: 128.84x
Market Cap: $1.95B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Syndax Pharmaceuticals Inc in?

Syndax Pharmaceuticals Inc (SNDX) operates in the Pharmaceutical Preparations industry.

What is SNDX's market cap?

Syndax Pharmaceuticals Inc (SNDX) has a market capitalization of $1.95B as of 2026-06-30.

What exchange does SNDX trade on?

Syndax Pharmaceuticals Inc (SNDX) trades on the Nasdaq.

Where is Syndax Pharmaceuticals Inc incorporated?

Syndax Pharmaceuticals Inc is incorporated in DE.